TransCode Therapeutics EBIT

The latest EBIT for RNAZ is $16M as of June 2026. That compares with $-10M in the prior-year period — up 260.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside TransCode Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNAZ's EBIT moved from $-10M to $16M — a 260.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TransCode Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, RNAZ currently prints $16M for EBIT, while the sector average sits near $22B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at TransCode Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $16M for RNAZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting RNAZ's EBIT ($16M), review year-over-year change from $-10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.